Danuglipron Tracker App

Danuglipron ist ein in der Entwicklung befindliches orales GLP-1-Medikament von Pfizer. Es zielt darauf ab, die Vorteile von injizierbaren GLP-1-Therapien in Tablettenform anzubieten.

Shotlee erfasst jeden Aspekt Ihres Danuglipron-Protokolls: Einnahmezeiten, Dosierungen, Nebenwirkungen, Gewichtsveränderungen und Laborergebnisse. Präzise Daten sind der Schlüssel zum Erfolg.

The Khavinson peptide bioregulators represent a unique pharmacological concept — organ-specific short peptides (2–4 amino acids) that restore age-related gene expression deficits in specific tissues.

Vladimir Khavinson's research at the St. Petersburg Institute over 40+ years showed that tissue-specific peptides act as epigenetic regulators — binding to chromatin in target organ cells and activating gene transcription pathways that decline with aging.

Cortagen, derived from adrenal cortex, contains these organ-specific signal peptides in a small oral bioavailable form. The proposed mechanism: adrenal cortex cells have specific receptors or chromatin-binding sites for Cortagen's peptide fractions.

Upon binding, they activate gene expression for steroidogenesis enzymes and cortisol production pathways — restoring the adrenal cortex's functional capacity toward a younger, more responsive state. Unlike direct cortisol supplementation (which suppresses the HPA axis through negative feedback), Cortagen is believed to restore intrinsic adrenal capacity — a fundamentally different and potentially safer approach to adrenal support.

Adrenal fatigue — a pattern of exhausted HPA axis function characterized by blunted cortisol awakening response, low-normal total cortisol, excessive fatigue, poor stress tolerance, and disrupted sleep — is a common manifestation of prolonged psychological and physiological stress.

While disputed as a formal medical diagnosis, the HPA axis dysregulation pattern it describes is real and measurable via salivary cortisol testing. Cortagen is used by practitioners in the Khavinson system specifically to address this pattern.

The targeted organs are: adrenal cortex (Cortagen), hypothalamus-pituitary axis (Epitalon/Epithalamin), and thyroid (Thyreogen) — often used together for comprehensive HPA recovery. Clinical reports and Khavinson's own studies describe improved cortisol patterns, enhanced stress resilience, and reduced fatigue with 2–4 cycles of adrenal biopeptides.

The 10 mg oral dose is convenient (no injection required), well-tolerated, and compatible with simultaneous use of other bioregulators in the Khavinson system.

Cortagen is used to support adrenal cortex function and cortisol regulation, primarily in contexts of: (1) Adrenal fatigue — HPA axis dysfunction from chronic stress, characterized by exhaustion, poor stress tolerance, and abnormal cortisol patterns.

(2) Age-related adrenal decline — adrenal cortex cells lose functional capacity with aging, leading to reduced cortisol and DHEA production that impairs energy, immunity, and stress resilience. (3) Post-illness recovery — after significant illness or surgery that stressed the adrenal axis.

(4) Anti-aging protocols — as part of comprehensive Khavinson bioregulator regimens to maintain organ function and slow biological aging. Cortagen is typically combined with other tissue bioregulators: Epitalon (pineal), Thymalin (thymus), and Thyreogen (thyroid) for comprehensive neuroendocrine support.

The Khavinson system philosophy: restoring multiple organs simultaneously produces synergistic benefits that exceed single-organ restoration.

Cortagen differs fundamentally from direct cortisol or hydrocortisone supplementation.

Direct cortisol supplementation provides exogenous glucocorticoid — it relieves symptoms by substituting for adrenal output but suppresses the HPA axis through negative feedback, potentially worsening adrenal atrophy with prolonged use.

Cortagen instead provides organ-specific peptide bioregulators that aim to restore the adrenal cortex's intrinsic steroidogenic capacity — stimulating the gland to produce its own cortisol more effectively rather than substituting for it.

This distinction makes Cortagen potentially valuable for milder HPA dysregulation where supporting endogenous function is preferable to supplementing with exogenous hormone. However, Cortagen is not a substitute for medically necessary cortisol supplementation (e.g., Addison's disease, secondary adrenal insufficiency diagnosed by endocrinologists) — those conditions require pharmacological corticosteroid therapy.

Yes — Cortagen is designed to be combined with other Khavinson bioregulators as part of a multi-organ restoration approach.

Common combination protocols: (1) Cortagen + Epitalon — adrenal support combined with pineal gland bioregulation (melatonin, circadian rhythms); particularly relevant for cortisol-sleep cycle dysregulation.

(2) Cortagen + Thymalin — adrenal plus thymic support; addresses immune-HPA axis interaction that is commonly disrupted in chronic stress and aging. (3) Cortagen + Thyreogen — adrenal plus thyroid support; thyroid and adrenal function are intimately linked and often dysregulate together.

(4) Full Khavinson panel — all 4+ bioregulators taken simultaneously for comprehensive anti-aging; protocols using 5–10 bioregulators simultaneously have been studied in Khavinson's longitudinal aging research.

When combining bioregulators, use each at standard doses (10 mg/day oral) simultaneously or sequentially; the peptides are organ-specific so there is no pharmacological interaction concern. Track each on Shotlee for a complete protocol record.